Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DNM2 | P50570 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2495475 | 0.86 | KCNH2 (0.48) | KCNH2DNM2PTGS2CYP3A4PI4KA | |
| SCHEMBL1685607 | 0.84 | KCNH2 (0.52) | KCNH2DNM2PTGS2CYP3A4PI4KA | |
| SCHEMBL11815923 | 0.77 | PTGS2 (0.42) | KCNH2PTGS2CYP3A4MAPTALDH1A1 | |
| SCHEMBL2052342 | 0.77 | NOS2 (0.44) | KCNH2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1444830 | 0.77 | KCNH2 (0.41) | KCNH2PTGS2CYP3A4PI4KAPI4K2B | |
| SCHEMBL24798597 | 0.77 | KCNH2 (0.46) | KCNH2DNM2PTGS2CYP3A4NOS2 | |
| SCHEMBL21503637 | 0.73 | CA2 (0.43) | KCNH2PTGS2CYP3A4PI4KAPI4K2B | |
| SCHEMBL11440331 | 0.73 | DNM2 (0.39) | KCNH2DNM2PTGS2CYP3A4PI4KA | |
| SCHEMBL20197182 | 0.72 | KCNH2 (0.44) | KCNH2PTGS2CYP3A4GABRPGABRD | |
| SCHEMBL24974007 | 0.72 | CA2 (0.42) | KCNH2DNM2PTGS2GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180009764-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2018-01-11 | — | — | US | disclosed |
| US-20150368207-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2015-12-24 | — | — | US | disclosed |
| US-9162987-B2 | Iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (MIF)-implicated diseases and conditions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20130079361-A1 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | ADVANCED CANCER THERAPEUTICS, LLC | 2013-03-28 | — | — | US | disclosed |
| EP-2480235-A2 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | University Of Louisville Research Foundation, Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011038234-A2 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079361-A1 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | MIF, MSR1, CCL2 | KCNH2 4451/4885DNM2 4134/4885PTGS2 400/4885 |
| US-20180009764-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | MIF, MSR1, CCL2 | KCNH2 4071/4885DNM2 4075/4885PTGS2 254/4885 |
| US-20150368207-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | MIF, MSR1, CCL2 | KCNH2 4071/4885DNM2 4075/4885PTGS2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.